Effect of levosimendan infusion prior to left ventricular assist device implantation on right ventricular failure

Amitai Segev1,2*, Jacob Lavee1,2, Yigal Kassif1, Yedida Shemesh1, Alexander Kogan1, Dov Freimark1,2, Avi Morgan1, Dor Lotan1,2, Edward Itelman1 and Avishay Grupper1,2

Abstract

Objective: Investigate the safety and efficacy of preoperative levosimendan in patients undergoing left ventricular assist device (LVAD) implantation.

Methods: Consecutive patients who received LVADs (HeartMate-2, 3, HVAD) in a single tertiary medical center (2012–2018). INTERMACS profile 1 patients were excluded. The primary outcome was post-LVAD right ventricular failure (RVF) and inhospital mortality rates. The secondary outcomes included other clinical, echocardiographic and hemodynamic parameters at follow-up.

Results: Final cohort consisted of 62 patients (40[65%] in the levosimendan group and 22[35%] in the no-levosimendan group). Post-operative RVF rate and inotrope or ventilation support time were similar in the levosimendan and no-levosimendan groups (7.5% vs. 13.6%; \(P = 0.43\), median of 51 vs. 72 h; \(P = 0.41\) and 24 vs. 27 h; \(P = 0.19\), respectively). Length of hospitalization, both total and in the intensive care unit, was not statistically significant (median days of 13 vs. 16; \(P = 0.34\), and 3 vs. 4; \(P = 0.44\), respectively). Post-operative laboratory and echocardiographic parameters and in-hospital complication rate did not differ between the groups, despite worse baseline clinical parameters in the Levosimendan group. There was no significant difference in the in-hospital and long term mortality rate (2.5% vs. 4.5%; \(P > 0.999\) and 10% vs. 27.3% respectively; \(P = 0.64\)).

Conclusions: Levosimendan infusion prior to LVAD implantation was safe and associated with comparable results without significant improved post-operative outcomes, including RVF.

Keywords: LVAD, Levosimendan, Left ventricular assist device, Right ventricular failure

Introduction

Left ventricular (LV) assist devices (LVADs) are an increasingly common therapy for advanced heart failure (HF). At present, LVADs represent the only available and effective alternative to heart transplantation, and provide a broad spectrum of strategies, including bridge to heart transplantation (BTT), bridge to recovery and destination therapy (DT).

Given that many patients with advanced LV dysfunction assessed for an LVAD also have some degree of right ventricular (RV) dysfunction, early RV failure (RVF) immediately after device implantation is a common complication affecting 10–40% of the patients [1].

Post LVAD implantation RVF (post-LVAD RVF) develops through multiple mechanisms, including increased venous return to the RV, decreased septal contribution to RV contraction, exacerbation of tricuspid regurgitation...
(TR) and tachyarrhythmias [2–5]. Clinical manifestations of post-LVAD RVF include systemic congestion, end-organ dysfunction, and/or circulatory failure [6]. Specific diagnostic criteria for RVF after CF-LVAD implantation have not been universally defined [7–9].

With accordance to previous studies, including the pivotal MOMENTUM-3 trial [10], post-LVAD RVF was considered as a need for right ventricular assist device (RVAD) support or inotrope support for longer than 7 days after the surgery [7, 11].

Post-LVAD RVF confers worse prognosis and constitutes a major cause of morbidity and mortality in the early post-operative period [12, 13].

Levosimendan is an inodilator that increases cardiac contractility via calcium sensitization [14]. Several studies investigating the effect of perioperative levsimendan in patients undergoing cardiac surgery did not show a clear clinical benefit, and the effect of levsimendan in the context of RVF is still unclear [15–17].

There is very little data on the safety and efficacy of preoperative levsimendan infusion in patients undergoing LVAD implantation. The objective of this study was to investigate the effect of preoperative levsimendan administration on post-operative RVF and other clinical, laboratory, echocardiographic and hemodynamic outcomes.

Patients and methods
A retrospective analysis of all consecutive patients who received continuous flow LVADs (Heartmate 2, 3 or HVAD) between August 2012 and May 2018 at a single tertiary medical center. All patients underwent a comprehensive evaluation before implantation according to local protocols, perioperative hospitalization in the cardiac surgery department and routine follow-up post-implantation at the LVAD clinic in our heart failure institute. Patients classified as INTERMACS 1 (cardiogenic shock) [18] prior to LVAD implantation and patients who were implanted a biventricular assist (BIVAD) device were excluded from the study.

The study was approved by the Institutional Ethics Committee. Consent of patients has been waived. The data underlying this article will be shared on reasonable request to the corresponding author.

Pre and post-operative data (demographic, clinical, echocardiographic, hemodynamic and laboratory) for each patient were abstracted from the medical records. Of note, most pre-operative right heart studies were performed after medical optimization, including levsimendan administration. CKD was defined as estimated creatinine clearance of less than 60 mL/min/1.73 m² calculated by the MDRD formula. Pre-operative echocardiographic examinations were performed at 5 (range 1–149) days and hemodynamic catheterizations were performed at 41 (range 1–220) days before surgery. Post-operative echocardiographic examinations were performed during the index hospitalization and at 14 (range 0–117) days and hemodynamic catheterizations were performed at 6 (range 1.3–13.1) months after surgery. Post-operative complications were defined according to the society of thoracic surgeons definitions for post coronary artery bypass graft surgeries including deep sternal wound infection, bleeding, renal failure, surgical re-exploration, prolonged ventilation and stroke [19]. We also included other relevant complications including ventricular or atrial arrhythmia and postpericardiotomy syndrome (PPS). As previously mentioned, RVF was defined as inotropic support for over 7 days.

Patients were stratified into two groups based on preoperative levsimendan infusion (levosimendan group vs. no-levosimendan group). Up to November 2016 the decision whether to administer preoperative levsimendan was left to the physician discretion. After that point in time, all patients received preoperative levsimendan as part of an institutional protocol.

Preoperative, intraoperative and post-operative clinical, laboratory, echocardiographic and hemodynamic parameters were compared between the groups.

Statistical analysis
Categorical variables were described as frequency and percentage and continuous variables as median and interquartile range (IQR). Continuous variables were compared between the two groups using Mann–Whitney Test and categorical variables were compared using Chi-Square Test of Fischer’s Exact Test.

Length of follow up was observed using reversed censoring method. Kaplan–Meier curve was used to describe events (mortality, transplant, complications etc.) during the follow up period, and Log-Rank test was used to compare between the groups. Multivariable analysis was performed using Cox Regression Model for events with a known duration to the event and a General Bimomial Logistic Regression for events without an unknown time to event.

All statistical tests were two sided and \( P < 0.05 \) was considered as statistically significant.

SPSS was used for all statistical analysis (IBM SPSS Statistics, version 25, IBM corp, Armonk, NY, USA, 2017).

Results
Patient characteristics
The study cohort consisted of 62 patients (88.7% males) who underwent LVAD implantation, after exclusion of patients with an INTERMACS 1 score prior to implantation surgery \((n = 2)\), patients who underwent a BIVAD
implantation (n = 4), patients with both (n = 2) and patients with missing data regarding preoperative levo-
simendan treatment (n = 1). No race-based differences were present.

The median follow-up period was 21 months (IQR 14–31).

Patients were implanted with a HeartMate 2 device (implantations up to January 1st 2016, n = 20),
HeartMate 3 device (implantations after January 1st 2016, n = 39), or a HeartWare device (n = 3).

The main HF etiology in both groups was ischemic cardiomyopathy followed by idiopathic dilated cardio-
myopathy. The majority of patients in both groups were implanted as part of a BTT (total of 90.3%). All patients
were severely symptomatic (Table 1).

| Characteristic          | Pre-op levosimendan (n = 40) | No-levosimendan (n = 22) | Total (n = 62) | P value |
|-------------------------|-------------------------------|--------------------------|----------------|---------|
| Age—yr                  | 57.3 (51.3–62.9)              | 57.2 (52.6–65.1)         | 57.2 (51.7–63.1) | 0.79    |
| Male sex                | 33 (82.5)                     | 22 (100)                 | 55 (88.7)      | 0.04    |
| HF etiology             |                               |                          |                | 0.16    |
| ICMP                    | 18 (45)                       | 14 (63.6)                | 32 (51.6)      |         |
| DCM                     | 21 (52.5)                     | 7 (31.8)                 | 28 (45.1)      |         |
| NYHA class              |                               |                          |                | 0.003   |
| 3B                      | 2 (5)                         | 8 (36.4)                 | 10 (16.1)      |         |
| 4                       | 38 (95)                       | 14 (63.6)                | 52 (83.9)      |         |
| INTERMACS score         |                               |                          |                | 0.08    |
| 2                       | 17 (42.5)                     | 6 (27.3)                 | 23 (37.1)      |         |
| 3                       | 9 (22.5)                      | 2 (9.1)                  | 11 (17.7)      |         |
| 4                       | 14 (35)                       | 14 (63.6)                | 28 (45.2)      |         |
| Diabetes mellitus       | 17 (42.5)                     | 9 (40.9)                 | 26 (41.9)      | 0.9     |
| Chronic kidney disease  | 13 (32.5)                     | 11 (50)                  | 24 (38.7)      | 0.17    |
| Creatinine—mg/dL        | 0.98 (0.73–1.39)              | 1.3 (1.09–1.6)           | 1.15 (0.83–1.44) | 0.01   |
| MDRD—mL/min/1.73 m²     | 78.4 (55.9–105.9)             | 61.5 (47.5–76.0)         | 68.2 (52.4–97.9) | 0.029 |
| Bilirubin—mg/dL         | 0.8 (0.56–1.17)               | 0.86 (0.68–1.7)          | 0.8 (0.62–1.24) | 0.27   |
| Albumin—g/dL            | 3.7 (3.4–4.0)                 | 4 (3.6–4.4)              | 3.8 (3.4–4.1)  | 0.024  |
| Echocardiography        |                               |                          |                |         |
| EF—%                    | 15 (10–20)                    | 17.5 (12.2–25.0)         | 15 (10–20.5)   | 0.27   |
| MR—above moderate       | 18 (45)                       | 7 (31.8)                 | 25 (40.3)      | 0.31   |
| TR—above moderate       | 4 (10)                        | 3 (13.6)                 | 7 (11.3)       | 0.69   |
| Enlarged RV             | 18 (40)                       | 7 (31.8)                 | 25 (40.3)      | 0.31   |
| RV function             |                               |                          |                | 0.15   |
| Normal                  | 6 (15)                        | 8 (36.4)                 | 14 (22.6)      |         |
| Mild reduction          | 13 (32.5)                     | 5 (22.7)                 | 18 (29)        |         |
| Moderate–severe reduction| 21 (52.5)                     | 9 (40.9)                 | 30 (48.4)      |         |
| SPAP—mmHg               | 55 (50.25–60)                 | 53 (41–60)               | 54.5 (48.75–60) | 0.55  |
| Right heart catheterization |                           |                          |                |         |
| CO—I/min               | 2.93 (2.48–3.67)              | 3.19 (2.53–3.69)         | 2.98 (2.5–3.68) | 0.48   |
| PCWP—mmHg               | 28 (23.75–31.5)               | 23.5 (18.75–30.25)       | 27 (21.25–31)  | 0.047  |
| mPA—mmHg                | 41.5 (34.5–46.5)              | 30 (30.5–46.5)           | 40 (33–46)     | 0.32   |
| mRA—mmHg                | 10 (7–13)                     | 8 (4–16.5)               | 9.5 (6–13)     | 0.56   |
| RA/PCWP                 | 0.37 (0.27–0.47)              | 0.37 (0.25–0.46)         | 0.37 (0.25–0.46) | 0.98 |
| PAPi                    | 3.75 (2.79–5.21)              | 4.75 (3.15–12)           | 4.5 (2.8–10.7) | 0.21   |
| PVR—wood units          | 3.17 (2.42–4.87)              | 4.02 (2.19–6.13)         | 3.41 (2.4–5.16) | 0.43   |

Data are presented as median (Interquartile range) or number (%)  
ICMP, ischemic cardiomyopathy; IDC, idiopathic dilated cardiomyopathy; SPAP, systolic pulmonary artery pressure; CO, cardiac output; PCWP, pulmonary capillary wedge pressure; mPA/RA, mean pulmonary artery/right atrium pressure; PAPi, pulmonary artery pulsatility index; PVR, pulmonary vascular resistance
The levosimendan and no-levosimendan groups did not differ in the baseline prevalence of ventricular or atrial tachyarrhythmias (62.5% vs. 41%; \( P = 0.1 \) and 47.5% vs. 60%; \( P = 0.38 \), respectively), the presence of an ICD or CRT apparatus (75% vs. 91%; \( P = 0.18 \) and 42.5% vs. 54.5%; \( P = 0.36 \), respectively) and the concurrent antiarrhythmic or digitalis therapy (60% vs. 54.5%; \( P = 0.67 \) and 37.5% vs. 50%; \( P = 0.34 \), respectively).

Baseline echocardiographic parameters were similar between the groups. The mean left ventricular ejection fraction (EF) was 15% (IQR 10–20.5). Almost half of the patients were considered to have at least moderate RV dysfunction (48.4%, \( n = 30 \)) and 11.3% (\( n = 7 \)) above moderate TR.

Hemodynamic data at baseline showed increased mean right atrial (mRA) and pulmonary (mPA) pressure in both groups. Despite elevated pulmonary capillary wedge pressure (PCWP) in the levosimendan group, both the ratio between RA to PWCP (RA/PCWP) and the pulmonary artery pulsatility index (PAPi) were similar between the groups. The levosimendan group had a significantly increased proportion of NYHA 4 patients and lower estimated creatinine clearance levels, compared to the no-levosimendan group.

### Short-term post-operative outcomes

Thirteen patients (21%) underwent a total of 17 additional surgical procedures during the LVAD surgery, including aortic valve replacement (\( n = 6 \)), tricuspid valve replacement (\( n = 7 \)), patent foramen ovale closure (\( n = 3 \)) and mitral clip removal (\( n = 1 \)), with similar rates between the groups (Table 2). LVAD speed, measured at day one after surgery and adjusted as standard deviation from average speed for each device, was similar in both groups (\( −0.15 \), IQR \([-0.1]–[-0.66]\) in the levosimendan group vs. \( −0.1 \), IQR \([-0.12]–[-0.54]\) in the no-levosimendan group; \( P = 0.36 \)). There was no difference in the post-operative inotrope and ventilation support time (median of 51 h vs. 72 h; \( P = 0.41 \) and 24 h vs. 27 h; \( P = 0.19 \), respectively), as well as the maximal central venous pressure (CVP) post-surgery (22 mmHg, IQR 17.75–26.25 vs. 23 mmHg, IQR 19–26; \( P = 0.58 \)).

| Outcome | Pre-op levosimendan (\( n = 40 \)) | No-levosimendan (\( n = 22 \)) | Total (\( n = 62 \)) | \( P \) value |
|---------|----------------------------------|-------------------------------|----------------------|-----------|
| Additional surgical procedures | 10 (25) | 3 (13.6) | 13 (21) | 0.34 |
| Cardiopulmonary bypass time—minutes | 93 (83.75–115.25) | 105 (87.5–127.5) | 97.5 (84.25–116.75) | 0.39 |
| Post-op ventilation support time—hours | 24 (22–29.75) | 27 (22–56.75) | 25 (22–48) | 0.19 |
| Maximal CVP—mmHg | 22 (18–26) | 23 (19–26) | 22 (19–26) | 0.58 |
| Post-op inotrope support time—hours | 51 (19–88) | 72 (18–125) | 60 (19–112) | 0.41 |
| Inotropic support > 14 days | 1 (2.5) | 1 (4.5) | 2 (3.2) | 0.66 |
| RVF | 3 (7.5) | 3 (13.6) | 6 (9.6) | 0.43 |
| Echocardiography at discharge | | | | |
| Enlarged RV | 14 (35) | 9 (40.9) | 23 (37.1) | > 0.999 |
| RV function | | | | 0.59 |
| Normal | 7 (24.1) | 5 (29.4) | 12 (19.4) | |
| Mild reduction | 4 (13.8) | 4 (23.5) | 8 (12.9) | |
| Moderate—severe reduction | 18 (62.1) | 8 (47.1) | 26 (41.9) | |
| Laboratory at discharge | | | | |
| Creatinine—mg/dL | 0.77 (0.63–1.02) | 0.99 (0.76–1.09) | 0.87 (0.69–1.09) | 0.073 |
| MDRD—mL/min/1.73 m² | 96.3 (78.4–143.3) | 83.8 (74.7–111.2) | 95.7 (81.1–132.1) | 0.19 |
| Bilirubin—mg/dL | 0.61 (0.44–0.9) | 0.68 (0.5–0.86) | 0.87 (0.69–1.09) | 0.39 |
| Albumin—g/dL | 3 (2.8–3.2) | 2.9 (2.6–3.1) | 2.9 (2.7–3.2) | 0.31 |
| Post-op Complications—Any | 15 (68.1) | 21 (52.5) | 36 (58) | 0.23 |
| Total hospitalization length—days | 13 (9.25–23.5) | 16 (10.75–25.75) | 14 (10–24.25) | 0.53 |
| ICU hospitalization length—days | 3 (2–5) | 4 (2–6) | 3.5 (2–6) | 0.44 |
| Short term mortality | | | | |
| During hospitalization | 1 (2.5) | 1 (4.5) | 2 (3.2) | > 0.999 |
| 30 days | 0 (0%) | 1 (4.5%) | 1 (1.6) | 0.76 |

Data are presented as median (Interquartile range) or number (%)
was also no difference in the number of inotropic drugs used, as three or more drugs were used at a similar rate in both groups (26% in the levosimendan group vs. 12% in the no-levosimendan group; \( P = 0.41 \)).

No patient in either group required RVAD support. The rate of post-LVAD RVF, defined as inotrope support for longer than 7 days, was similar between the levosimendan and no-levosimendan groups (7.5% vs. 13.6% respectively; \( P = 0.43 \)). Rate of inotropic support for more than 14 days was also similar between the groups (2.5% vs. 4.5% respectively; \( P = 0.66 \)).

Echocardiographic parameters before discharge were similar between the groups. The incidence of valvular abnormalities including the presence of above moderate aortic, mitral or tricuspid regurgitation did not differ between the groups (2.8% vs. 4.5%, 7.1% vs. 9.1%, 3.1% vs. 12.5% respectively; \( P > 0.1 \) for all). There was however a higher systolic pulmonary artery pressure (SPAP) in the levosimendan treated group (55 mmHg, IQR 50.2–60) compared to the control group (39 mmHg, IQR 37–49; \( P = 0.004 \)).

The median hospitalization time, both total and in the ICU, was similar between the groups. There was no statistically significant difference between the two groups in the rates of total or individual post-operative complications including deep sternal wound infection (no cases in both groups), bleeding (0% vs. 4.5%; \( P = 0.35 \)), renal failure (2.5% vs. 4.5%; \( P > 0.99 \)), surgical re-exploration (10% vs. 22.7%; \( P = 0.25 \)), prolonged ventilation (2.5% vs. 0%; \( P > 0.99 \)), stroke (no cases in both groups), pneumonia (7.5% vs. 13.6%; \( P = 0.65 \)), ventricular or atrial arrhythmia (10% vs. 4.5%; \( P = 0.64 \) and 12.5% vs. 13.6% \( P > 0.99 \)) and PPS (7.5% vs. 4.5%; \( P > 0.99 \), respectively).

The mortality rate during the hospitalization and at 30 days after the surgery were similar in the levosimendan and no-levosimendan groups (2.5% vs. 4.5%; \( P > 0.99 \) and 0% vs. 4.5%; \( P = 0.76 \), respectively).

### Long-term post-operative outcomes

Right heart studies performed at an average of 6 months after surgery (range 1.3–13.1) showed a lower CO and higher mRA pressure in the levosimendan group (Table 3).

There was a similar rate of total and individual long term complications in the levosimendan and no-levosimendan groups including infection (35% vs. 13.6%)

| Outcome                        | Pre-op levosimendan (n=40) | No-levosimendan (n=22) | Total (n=62) | P-value |
|--------------------------------|----------------------------|-------------------------|--------------|---------|
| NYHA class at 3 months         |                            |                         |              | 0.73    |
| 1–2                            | 32 (82.1)                  | 16 (76.2)               | 48 (77.4)    |         |
| 3–4                            | 7  (17.9)                  | 5 (23.8)                | 12 (19.4)    |         |
| Laboratory at 3 months         |                            |                         |              | 0.54    |
| Creatinine—mg/dL               | 0.9 (0.75–1.17)            | 0.94 (0.83–1.1)         | 0.93 (0.8–1.13) |         |
| Bilirubin—mg/dL                | 0.61 (0.44–0.9)            | 0.61 (0.5–0.74)         | 0.59 (0.49–0.72) | 0.47    |
| Albumin—g/dL                   | 3 (2.8–3.2)                | 3.4 (3.3–3.7)           | 3.9 (3.4–4.1) | 0.02    |
| Right heart catheterization    |                            |                         |              |         |
| CO—l/min                       | 4 (3.5–4.4)                | 4.4 (4.2–5.3)           | 4.3 (4.2–5.4) | 0.02    |
| PCWP—mmHg                      | 11 (8–17)                  | 9 (5–14)                | 10 (8–15)    | 0.15    |
| mPA—mmHg                       | 23 (18–27)                 | 19 (14–24)              | 21 (18–27)   | 0.21    |
| mRA—mmHg                       | 11 (8–14)                  | 5 (3–9)                 | 10 (6–13)    | 0.004   |
| PVR—wood units                 | 2.2 (1.7–3)                | 1.8 (1.7–1.9)           | 1.9 (1.7–2.7) | 0.52    |
| Readmissions                   |                            |                         |              |         |
| 14 days                        | 6 (15.4)                   | 3 (14.3)                | 9 (14.5)     | >0.99   |
| 3 months                       | 7 (17.9)                   | 5 (23.8)                | 12 (19.4)    | 0.73    |
| 1 year                         | 27 (69.2)                  | 13 (61.9)               | 40 (64.5)    | 0.56    |
| Long-term complications—Any    | 20 (50)                    | 9 (40.9)                | 29 (46.8)    | 0.46    |
| Long-term mortality—no         |                            |                         |              |         |
| 60 days                        | 1 (2.5%)                   | 1 (4.5%)                | 2 (3.2)      | >0.99   |
| 90 days                        | 1 (2.5%)                   | 1 (4.5%)                | 2 (3.2)      | >0.99   |
| Total                          | 4 (10)                     | 6 (27.3)                | 10 (16.1)    | 0.64    |

Data are presented as median (Interquartile range) or number (%)

RBC, red blood cells; CVP, central venous pressure; ICU, intensive care unit
P = 0.08), bleeding (15% vs. 36.4%; P = 0.09), thrombotic (5% vs. 9.1%; P = 0.67) and device technical malfunction events (0% vs. 4.5%; P = 0.18, respectively).

The overall mortality rate throughout the follow-up period did not differ between the groups (10% vs. 27.3%; P = 0.64) (Fig. 1).

Subanalysis of patients who received preoperative levosimendan before institutional protocol
Since preoperative levosimendan became a part of our institutional protocol during the study follow up period, we performed a subgroup analysis of patients who received preoperative levosimendan before it became part of the protocol (“group A”; n = 13) and compared them to those who were not treated with the drug during the same period (“group B”; n = 22) and to those who received the drug routinely thereafter (“group C”; n = 27). Most of the clinical, laboratory and hemodynamic parameters were not statistically different between the groups, except for a higher proportion of NYHA 4 patients in group A compared to group B and more INTERMACS 2 patients in group A compared to both groups (see Additional file 1: Table S1).

Multivariable analysis
In order to account for baseline differences between the levosimendan and no-levosimendan groups we performed a multivariable analysis that included age, NYHA and INTERMACS scores and baseline kidney functions. Even after adjustment for these variables, preoperative treatment with levosimendan was not associated with lower rates of mortality or post-LVAD RVF (see Additional file 1: Table S2 and S3, respectively). Due to low event rates, we were unable to perform a multivariable analysis on determinants associated with inotropic support for over 14 days.

Discussion
This is the largest study thus far to our knowledge to evaluate the clinical utility of levosimendan administration in patients awaiting LVAD implantation. In our study levosimendan infusion prior to LVAD implantation was safe, well tolerated and was not associated with increased adverse events. On the other hand, it was not associated with significant improved short or long term post-operative outcomes, including post-LVAD RVF.

Post-LVAD RVF is a common complication that confers worse prognosis. RVF or multisystem organ failure was found to be the leading cause of early mortality (30-day or during the index hospitalization) among patients after LVAD implantation [12, 13].

Levosimendan is an inodilator developed in the 1990s that increases cardiac contractility via calcium sensitization, promotes vasodilatation by opening of ATP-dependent potassium channels in vascular smooth muscle cells and mediates a cardioprotective effect by opening of ATP-dependent potassium channels in
cardiomyocytes’ mitochondria which in turn inhibits myocyte apoptosis [20].

Levosimendan is administered as a 24 h infusion and exhibits a rapid onset of action with maximal therapeutic effects occurring at days 1–3 post-infusion and extended cardiovascular therapeutic effect sustained for 2–3 weeks due to its long-acting active metabolites [14].

Several studies have evaluated the efficacy and safety of levosimendan in patients with HF. Despite improvement in indices of cardiac performance and HF, there is no clear evidence of short- or long-term clinical benefit [21–24]. Levosimendan is currently approved for intravenous use in some countries in Europe and South America, but remains investigational in the United States [21].

The effect of levosimendan in the context of RVF is unclear. A meta-analysis of 6 randomized controlled trials evaluating the efficacy and safety of levosimendan in patients with acute RVF with a variety of heart and lung diseases showed significant changes in echocardiographic measurements. Nonetheless, adverse events did not significantly improve following levosimendan treatment [15].

The role of perioperative levosimendan in patients undergoing cardiac surgery have been investigated in several studies with indications emerging that it can reduce the risk of low-output cardiac syndrome [25]. In a recent meta-analysis levosimendan use before cardiac surgery was associated with reduced mortality, low-output cardiac syndrome incidence and acute kidney injury events [26].

Data on the use of levosimendan as preoperative treatment before LVAD implantation surgery is scarce. In a study published in 2012 [27], Sponga et al. examined the hemodynamic and prognostic effect of levosimendan infusion in patients with borderline RV function before urgent LVAD implantation. The study included 21 patients admitted to the ICU before LVAD implantation due to severe refractory HF with evidence of impending multiorgan failure. No relevant side effects were documented, including arrhythmia, tachycardia or hypotension. Hemodynamic parameters have improved 48 h after levosimendan infusion: cardiac index increased by 21% (P = 0.014), PAP decreased by 12% (P = 0.003), PCWP and CVP both decreased by 15% (P = 0.028 and P = 0.016 respectively) and mixed venous oxygen saturation increased (P = 0.008). Despite the beneficial effects on RV hemodynamics prior to LVAD implantation surgery, levosimendan treatment did not prevent post-operative RVF, which occurred in 19% of the patients. The survival rate was 86% at 30 days and 57% at 1 and 2 years following LVAD support.

A later study [28] performed a post hoc analysis of 9 patients receiving levosimendan treatment pre-LVAD implantation surgery. All patients were classified as INTERMACS 2 due to deterioration of renal and hepatic function under inotropic therapy. Application of levosimendan was safe and 12-month survival rate was 89%. Two patients (22.2%) required post-operative temporary extracorporeal membrane oxygenation support due to intraoperative RVF. Data on other postoperative complications and readmission rate were not reported in this study.

Compared with the previous studies mentioned, our cohort included a larger number of patients and had a control group. The vast majority of patients in our study had RV function impairment before surgery, and almost 50% had at least moderate RVF per echo. Impaired RV function at baseline may have led to selection bias, and thus undermine any beneficial effect on RV function by levosimendan. However, we found a relatively low rate of post-LVAD RVF and mortality in our study, compared to the data cited in the literature above, rendering the last argument questionable. A possible explanation to the low event rate is the fact that most patients were hospitalized prior to LVAD implantation surgery, were medically optimized with inotrope and diuretic treatment and lacked clinical evidence of RVF at the time of surgery.

Another possible explanation to levosimendan’s lack of efficacy shown in our study is the difference in patients’ baseline characteristics between the groups, but even after adjusting for these variables, treatment with levosimendan was not associated with lower rates of mortality or post-LVAD RVF. Of note, both RA/PCWP ratio and PAPi were not significantly different between the two groups at baseline, further supporting their hemodynamic similarity. In a subgroup analysis we found that patients treated with levosimendan before it became the standard of practice at our institution were clinically more ill, as manifested by a higher proportion of NYHA 4 and INTERMACS 2 patients, and therefore were considered for an additional therapy to improve postoperative outcomes. The fact that despite worse clinical status at baseline the patients had similar outcomes might suggest a possible benefit of levosimendan therapy. Nevertheless, adjusted multivariable analysis did not support an independent association between levosimendan therapy and better clinical outcomes. Overall, despite a high proportion of critically ill patients with a substantial RV dysfunction at baseline in our study, we hereby report comparatively excellent results, including short hospitalization length and low post-LVAD RVF and mortality rate [1, 12, 27]. These observations including small sample size and low event rate of RVF and mortality in the patient cohort, may at least in part explain the lack of efficacy levosimendan exhibited in our study.
It is also important to mention the lack of adverse events including arrhythmias among the levosimendan treated patients compared with the no-levosimendan group. Due to the lack of adverse events on the one hand, in the face of a numerical improvement of outcomes in the levosimendan group and overall low event rates of mortality and post-LVAD RVF on the other, we maintained our policy of routine levosimendan administration before LVAD surgery at our institution. Our study can be thus seen as hypothesis forming and used as a foundation for further research.

We acknowledge some limitations to our study. First, this was an observational study with a retrospective analysis of collected data. Second, the study was conducted in a single tertiary medical center and there may have been patient selection bias. Third, as previously mentioned pre-operative treatment with levosimendan in our institution became the standard of practice towards the end of the study period. Of note, inotropic support for over 14 days was not included in the multivariable analysis due to the paucity of events in both groups. In addition, the decision whether to treat patients with other inotropes before the LVAD implantation was at the physician’s discretion and was not based on institution protocol. Therefore, potential confounders in that regard were not accounted for. Lastly, despite numerical differences in favor of levosimendan use, the small patient cohort and low event rate of post-LVAD RVF may lack the statistical power to identify significant differences in the outcomes measured. Nevertheless, this is the largest cohort addressing this clinical issue thus far.

**Conclusion**

In conclusion, in this study we have assessed the largest cohort of advanced HF patients treated with levosimendan prior to LVAD implantation surgery. Post-LVAD outcomes were comparable between patients with or without preoperative levosimendan, despite worse clinical parameters in the levosimendan group. Levosimendan infusion, although safe, was not associated with improved post-operative clinical, laboratory, echocardiographic or hemodynamic parameters. Future larger, randomized controlled prospective studies are warranted.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13019-022-01915-6.

Additional file 1. Supplementary material.

**Author contributions**

AS: Generation of concept, data collection, data analysis and interpretation, drafting article. JL: Generation of concept, critical revision of article, approval of article. YK: Critical revision of article, approval of article. DF: Generation of concept, critical revision of article, approval of article. AM: Generation of concept, critical revision of article, approval of article. AK: Critical revision of article, concept, drafting article, approval of article. GL: Data collection, statistical analysis. EK: Data collection, statistical analysis. AG: Generation of concept, drafting article, data analysis and interpretation, critical revision of article, approval of article. All authors read and approved the final manuscript.

**Funding**

No funding was received.

**Availability of data and materials**

The data underlying this article will be shared on reasonable request to the corresponding author.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Institutional Ethics Committee (4955-18-SMC). Consent of patients has been waived.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Cardiovascular Division, Sheba Medical Center, Tel Hashomer, Sheba Rd. 2, Ramat-Gan, Israel. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

**Received:** 3 February 2022   **Accepted:** 13 June 2022

**Published online:** 16 June 2022

**References**

1. Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Hear Lung Transplant. 2015;34(9):1123–30.
2. Farrar DJ, Compton PG, Hershon JJ, Fonger JD, Hill JD. Right heart interaction with the mechanically assisted left heart. World J Surg. 1985;9(1):89–102.
3. Farrar DJ. Ventricular interactions during mechanical circulatory support. Semin Thorac Cardiovasc Surg. 1994;6(3):163–8.
4. Krishan K, Nair A, Pinney S, Adams DH, Anyanwu AC. Liberal use of tricuspid valve annuloplasty during left-ventricular assist device implantation. Eur J Cardio-thorac Surg. 2012;41(1):213–7.
5. Brisco MA, Sundareswaran KS, Milano CA, Feldman D, Testani JM, Ewald GA, Slaughter MS, Farrar DJ, Goldberg LR. The incidence, risk, and consequences of atrial arrhythmias in patients with continuous-flow left ventricular assist devices. J Card Surg. 2014;29(4):572–80.
6. Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. Anesth Analg. 2009;108:423–33.
7. Ali HJR, Kiernan MS, Choudhary G, Levine DJ, Sodha NR, Ehsan A, Yousefzai R. Right ventricular failure post-implantation of left ventricular assist device: prevalence, pathophysiology, and predictors. ASAIO J. 2020;66(6):610–9.
8. Bellavia D, Iacovoni S, Scardulla C, Moja L, Pilato M, Kushwaha SS, Senni M, Clemenza F, Agnese V, Falletta C, Romano G, Maalouf J, Dandel M. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies. Eur J Heart Fail. 2017;19:926–46.
9. Cogswell R, John R, Shaffer A. Right ventricular failure after left ventricular assist device. Cardiol Clin. 2020;38(2):219–25.
10. Mehrab MR, Urel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, Ransom J, Ewald GA, Iroh A, Raval NY, Silvestry SC, Cogswell R, John R, Bhimaraj A, Bruckner BA, Lowes BD, Um JY, Jeevanandam V, Sayer G, Mangi AA, Molina EJ, Sheikh...
F. Aaronson K, Pagani FD, Cotts WG, Tatooles AJ, Babu A, Chomsky D, Katz JN, Tessmann PB, Dean D, Krishnamoorthy A, Chuang J, Topuria I, Sood P, Goldenstein DJ. A fully magnetically levitated left ventricular assist device—final report. N Engl J Med. 2019;380(17):1618–27.

11. Topolinsky Y, Qi, JK, Shah DK, Boisson BA, Schirger JA, Kushwaha SS, Pereira NL, Park SJ. Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation. JACC Cardiovasc Imaging. 2011;4(3):211–22.

12. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080–6.

13. Stulak JM, Mehta V, Schirger JA, Aaronson KD, Joyce LD, Daly RC, Pagani FD, Maltais S. Temporal differences in causes of mortality after left ventricular assist device implantation. Ann Thorac Surg. 2015;99(6):1969–74.

14. Kivikki M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42(1):43–51.

15. Qiu J, Jia L, Hao Y, Huang S, Ma Y, Li X, Wang M, Mao Y. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017;184:30–6.

16. Mehta RH, Leimberger JD, Van Diepen S, Meza J, Wang A, Jankovich R, Harrison RW, Hay D, Fresmes S, Duncan A, Soltesz EG, Luber J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, Alexander JH. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376(21):2032–42.

17. Landoni G, Lemovrotov VV, Alvaro G, Lobreglio R, Pisano A, Guerracino F, Calabrò MG, Grigoryev EV, Likhwantev VV, Salgado-Filho MF, Bianchi A, Pasyuga VV, Baichochi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376(21):2021–31.

18. Interagency Registry for Mechanically Assisted Circulatory Support. Manual of Operations and Procedures. 2014.

19. Performance Measure Descriptions|STS [Internet]. Cited 26 Jan 2020. https://www.sts.org/quality-safety/performance-measures/descriptions#CABGCompositeScore.

20. Haikala H. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27(9):1859–66.

21. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27(16):1908–20.

22. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investig Circ. 2000;102(18):2222–7.

23. Moiseyev VS, Roder P, Andrejevs N, Ruda MY, Golikov AP, Calvin-Colet J, Pollesello P, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020a.e19.

24. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peukhuirinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell E-P, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (London, England). 2002;360(9328):196–202.

25. Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, Černý V, Comin-Colet J, Pollesello P et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020a.e19.

26. Weber C, Esser M, Eghbalzadeh K, Sabashnikov A, Djordjevic I, Maer J, Merkle J, Choi YH, Madershahian N, Liakopoulos D, Deppe AC, Wahlen TC. Levosimendan reduces mortality and low cardiac output syndrome in cardiac surgery. Thorac Cardiovasc Surg. 2019;68(5):401–9.

27. Sponga S, Ivanitskia E, Potapov E, Krabatsch T, Hetzer R, Lehmkohl H. Preoperative treatment with levosimendan in candidates for mechanical circulatory support. ASAIO J. 2011;58(1):6–11.

28. Theiss HD, Grabmaier U, Kreissl N, Hagl C, Steinbeck G, Sodian R, Franz W-M, Kaczmarek I. Preconditioning with levosimendan before implantation of left ventricular assist devices. Artif Organs. 2014;38(3):231–4.